| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Delirium | 46 | 2021 | 1061 | 7.33 | Why? |
| Suicide, Assisted | 4 | 2018 | 36 | 2.26 | Why? |
| Euthanasia | 3 | 2018 | 21 | 1.60 | Why? |
| Critical Illness | 32 | 2021 | 17281 | 1.29 | Why? |
| Intensive Care Units | 35 | 2021 | 29594 | 1.23 | Why? |
| Critical Care | 18 | 2021 | 14081 | 1.13 | Why? |
| Hypnotics and Sedatives | 7 | 2021 | 624 | 1.06 | Why? |
| Coma | 4 | 2021 | 204 | 1.02 | Why? |
| Life Support Systems | 1 | 2020 | 5 | 0.89 | Why? |
| Cognition | 3 | 2018 | 1394 | 0.80 | Why? |
| Deep Sedation | 3 | 2018 | 121 | 0.76 | Why? |
| Emergence Delirium | 1 | 2018 | 15 | 0.74 | Why? |
| Psychomotor Agitation | 3 | 2017 | 208 | 0.73 | Why? |
| Fish Oils | 1 | 2018 | 33 | 0.71 | Why? |
| Pancreatic Pseudocyst | 1 | 2017 | 23 | 0.70 | Why? |
| Palliative Care | 6 | 2021 | 2665 | 0.70 | Why? |
| Boric Acids | 1 | 2017 | 2 | 0.70 | Why? |
| Pancreatitis, Chronic | 1 | 2017 | 37 | 0.69 | Why? |
| Institutionalization | 1 | 2017 | 81 | 0.69 | Why? |
| Translating | 1 | 2017 | 80 | 0.69 | Why? |
| Cognitive Dysfunction | 6 | 2018 | 1389 | 0.64 | Why? |
| Bioethics | 1 | 2020 | 253 | 0.62 | Why? |
| Methamphetamine | 1 | 2017 | 82 | 0.61 | Why? |
| Confusion | 2 | 2017 | 256 | 0.61 | Why? |
| Patient Care Bundles | 4 | 2018 | 137 | 0.59 | Why? |
| Hallucinations | 1 | 2017 | 122 | 0.58 | Why? |
| Withholding Treatment | 2 | 2020 | 798 | 0.57 | Why? |
| Cooperative Behavior | 2 | 2020 | 1216 | 0.57 | Why? |
| Physicians | 5 | 2021 | 4214 | 0.50 | Why? |
| Catatonia | 3 | 2020 | 102 | 0.50 | Why? |
| Hospitals, Community | 1 | 2017 | 475 | 0.48 | Why? |
| Terminology as Topic | 1 | 2018 | 546 | 0.47 | Why? |
| Airway Extubation | 1 | 2017 | 403 | 0.46 | Why? |
| Terminal Care | 2 | 2018 | 928 | 0.42 | Why? |
| Physician-Patient Relations | 1 | 2021 | 1266 | 0.41 | Why? |
| Respiration, Artificial | 14 | 2021 | 22116 | 0.41 | Why? |
| Ventilator Weaning | 3 | 2017 | 536 | 0.39 | Why? |
| Dementia | 2 | 2020 | 1861 | 0.39 | Why? |
| Lorazepam | 2 | 2020 | 70 | 0.39 | Why? |
| S100 Proteins | 1 | 2008 | 25 | 0.38 | Why? |
| Nerve Growth Factors | 1 | 2008 | 30 | 0.37 | Why? |
| Haloperidol | 2 | 2019 | 78 | 0.36 | Why? |
| Continuous Positive Airway Pressure | 1 | 2017 | 1187 | 0.35 | Why? |
| Perioperative Care | 1 | 2018 | 1329 | 0.33 | Why? |
| Prospective Studies | 25 | 2021 | 43301 | 0.33 | Why? |
| Activities of Daily Living | 5 | 2018 | 1530 | 0.32 | Why? |
| Shock, Septic | 1 | 2017 | 1313 | 0.32 | Why? |
| Patient Selection | 1 | 2020 | 4560 | 0.30 | Why? |
| Dexmedetomidine | 3 | 2018 | 130 | 0.30 | Why? |
| Dietary Supplements | 1 | 2018 | 2251 | 0.29 | Why? |
| Length of Stay | 6 | 2018 | 11042 | 0.29 | Why? |
| Brain Diseases | 1 | 2017 | 1463 | 0.29 | Why? |
| Cognition Disorders | 3 | 2018 | 574 | 0.26 | Why? |
| Humans | 83 | 2021 | 930598 | 0.26 | Why? |
| Antipsychotic Agents | 3 | 2018 | 887 | 0.26 | Why? |
| Brain Injuries | 1 | 2008 | 374 | 0.25 | Why? |
| Survivors | 4 | 2019 | 2619 | 0.25 | Why? |
| Postoperative Complications | 2 | 2018 | 5861 | 0.24 | Why? |
| Aged | 38 | 2021 | 215776 | 0.23 | Why? |
| Brain | 3 | 2017 | 5133 | 0.22 | Why? |
| Absorptiometry, Photon | 2 | 2018 | 168 | 0.21 | Why? |
| Heart Diseases | 1 | 2018 | 3503 | 0.21 | Why? |
| Male | 47 | 2021 | 367725 | 0.21 | Why? |
| Tennessee | 2 | 2018 | 243 | 0.20 | Why? |
| Nervous System Diseases | 1 | 2018 | 4092 | 0.20 | Why? |
| Dopamine Antagonists | 1 | 2018 | 13 | 0.20 | Why? |
| Behavior Observation Techniques | 1 | 2018 | 16 | 0.19 | Why? |
| Dialysis | 1 | 2018 | 45 | 0.19 | Why? |
| Female | 45 | 2021 | 380317 | 0.19 | Why? |
| Piperazines | 2 | 2019 | 445 | 0.19 | Why? |
| Neuropsychological Tests | 3 | 2019 | 954 | 0.18 | Why? |
| Therapy, Computer-Assisted | 1 | 2018 | 39 | 0.18 | Why? |
| Flecainide | 1 | 2017 | 4 | 0.18 | Why? |
| Stress, Psychological | 2 | 2020 | 10231 | 0.18 | Why? |
| Arab World | 1 | 2017 | 31 | 0.18 | Why? |
| Body Height | 1 | 2018 | 100 | 0.18 | Why? |
| Pain Measurement | 2 | 2018 | 533 | 0.18 | Why? |
| Ventilator-Induced Lung Injury | 1 | 2021 | 260 | 0.18 | Why? |
| Medication Reconciliation | 1 | 2018 | 41 | 0.18 | Why? |
| Europe, Eastern | 1 | 2017 | 88 | 0.18 | Why? |
| Manuals as Topic | 1 | 2017 | 6 | 0.18 | Why? |
| Laryngeal Diseases | 1 | 2018 | 60 | 0.17 | Why? |
| Analgesia | 1 | 2020 | 211 | 0.17 | Why? |
| Pain Management | 4 | 2020 | 854 | 0.17 | Why? |
| Simvastatin | 1 | 2017 | 63 | 0.17 | Why? |
| Larynx | 1 | 2018 | 126 | 0.17 | Why? |
| Attitude to Death | 2 | 2018 | 307 | 0.17 | Why? |
| Midazolam | 1 | 2017 | 79 | 0.17 | Why? |
| Anthropometry | 1 | 2018 | 233 | 0.17 | Why? |
| Arm | 1 | 2018 | 159 | 0.17 | Why? |
| Thiazoles | 2 | 2019 | 496 | 0.16 | Why? |
| Middle Aged | 36 | 2021 | 270681 | 0.16 | Why? |
| Vision Disorders | 1 | 2020 | 260 | 0.16 | Why? |
| Hearing Loss | 1 | 2020 | 225 | 0.16 | Why? |
| Executive Function | 1 | 2018 | 173 | 0.16 | Why? |
| Pilot Projects | 4 | 2019 | 5182 | 0.16 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.16 | Why? |
| Long Term Adverse Effects | 1 | 2017 | 119 | 0.16 | Why? |
| Reproducibility of Results | 7 | 2018 | 11304 | 0.16 | Why? |
| Attitude of Health Personnel | 4 | 2018 | 4741 | 0.16 | Why? |
| Psychometrics | 3 | 2018 | 1269 | 0.16 | Why? |
| Intubation | 1 | 2018 | 437 | 0.16 | Why? |
| Respiratory Mechanics | 1 | 2020 | 585 | 0.16 | Why? |
| Central Nervous System Stimulants | 1 | 2017 | 111 | 0.15 | Why? |
| Benzodiazepines | 1 | 2017 | 163 | 0.15 | Why? |
| Professional-Patient Relations | 1 | 2020 | 426 | 0.15 | Why? |
| Purines | 1 | 2021 | 816 | 0.15 | Why? |
| Analgesics, Non-Narcotic | 2 | 2018 | 164 | 0.15 | Why? |
| Birth Weight | 1 | 2017 | 250 | 0.15 | Why? |
| Azetidines | 1 | 2021 | 722 | 0.15 | Why? |
| Insecticides | 1 | 2017 | 178 | 0.14 | Why? |
| Double-Blind Method | 4 | 2021 | 5988 | 0.14 | Why? |
| Neurons | 1 | 2021 | 864 | 0.14 | Why? |
| Professional-Family Relations | 1 | 2020 | 424 | 0.14 | Why? |
| Interdisciplinary Research | 1 | 2017 | 266 | 0.14 | Why? |
| Risk Factors | 10 | 2021 | 71621 | 0.14 | Why? |
| Antibodies | 1 | 2021 | 846 | 0.14 | Why? |
| Cardiac Surgical Procedures | 2 | 2018 | 1931 | 0.14 | Why? |
| United States | 8 | 2020 | 46150 | 0.14 | Why? |
| Pain, Postoperative | 1 | 2018 | 289 | 0.14 | Why? |
| Body Composition | 1 | 2018 | 414 | 0.14 | Why? |
| Emergency Service, Hospital | 2 | 2017 | 14232 | 0.14 | Why? |
| End Stage Liver Disease | 1 | 2019 | 418 | 0.14 | Why? |
| Endothelium | 1 | 2018 | 460 | 0.14 | Why? |
| Fatty Acids, Omega-3 | 1 | 2018 | 306 | 0.14 | Why? |
| Anti-Arrhythmia Agents | 1 | 2017 | 325 | 0.14 | Why? |
| S100 Calcium Binding Protein beta Subunit | 2 | 2018 | 63 | 0.14 | Why? |
| Wounds and Injuries | 1 | 2007 | 1708 | 0.13 | Why? |
| Tachycardia, Ventricular | 1 | 2017 | 251 | 0.13 | Why? |
| Shock | 2 | 2018 | 1868 | 0.13 | Why? |
| Drainage | 1 | 2017 | 414 | 0.13 | Why? |
| Costs and Cost Analysis | 1 | 2018 | 694 | 0.13 | Why? |
| Practice Guidelines as Topic | 2 | 2017 | 15421 | 0.13 | Why? |
| Standard of Care | 1 | 2020 | 1297 | 0.13 | Why? |
| Mediastinal Emphysema | 1 | 2021 | 519 | 0.13 | Why? |
| Knowledge | 1 | 2017 | 452 | 0.13 | Why? |
| Analgesics | 1 | 2017 | 451 | 0.13 | Why? |
| Patient Care Team | 4 | 2020 | 3556 | 0.12 | Why? |
| Poland | 2 | 2018 | 2368 | 0.12 | Why? |
| Early Ambulation | 3 | 2017 | 102 | 0.12 | Why? |
| Sulfonamides | 1 | 2021 | 1294 | 0.12 | Why? |
| Pneumonia, Viral | 8 | 2020 | 243684 | 0.12 | Why? |
| Coronavirus Infections | 8 | 2020 | 253789 | 0.12 | Why? |
| Safety | 1 | 2020 | 1583 | 0.12 | Why? |
| Infant, Premature | 1 | 2017 | 883 | 0.11 | Why? |
| Ethics, Medical | 1 | 2018 | 533 | 0.11 | Why? |
| Adult | 20 | 2021 | 244371 | 0.11 | Why? |
| Belgium | 1 | 2018 | 2064 | 0.11 | Why? |
| Surgical Procedures, Operative | 1 | 2007 | 2662 | 0.11 | Why? |
| Intensive Care Units, Neonatal | 1 | 2017 | 749 | 0.11 | Why? |
| Apoptosis | 1 | 2021 | 2335 | 0.11 | Why? |
| Critical Care Nursing | 1 | 2017 | 469 | 0.11 | Why? |
| Pyrazoles | 1 | 2021 | 1791 | 0.11 | Why? |
| Delivery of Health Care | 1 | 2017 | 15909 | 0.11 | Why? |
| Disabled Persons | 2 | 2018 | 1152 | 0.11 | Why? |
| Patient Discharge | 4 | 2020 | 5696 | 0.10 | Why? |
| Diagnosis, Differential | 2 | 2017 | 7220 | 0.10 | Why? |
| Intensive Care Units, Pediatric | 1 | 2017 | 1098 | 0.10 | Why? |
| California | 1 | 2017 | 2047 | 0.10 | Why? |
| Diagnostic Techniques and Procedures | 1 | 2012 | 265 | 0.10 | Why? |
| Drug Prescriptions | 1 | 2018 | 1062 | 0.10 | Why? |
| Quality of Life | 4 | 2019 | 9820 | 0.10 | Why? |
| Self Report | 2 | 2018 | 3802 | 0.10 | Why? |
| Phenotype | 1 | 2020 | 4037 | 0.10 | Why? |
| Exercise Therapy | 1 | 2018 | 976 | 0.10 | Why? |
| Organ Dysfunction Scores | 1 | 2016 | 1475 | 0.10 | Why? |
| Hospitalization | 4 | 2020 | 54280 | 0.09 | Why? |
| Logistic Models | 3 | 2018 | 9089 | 0.09 | Why? |
| Treatment Outcome | 6 | 2021 | 51732 | 0.09 | Why? |
| Aged, 80 and over | 9 | 2020 | 88759 | 0.08 | Why? |
| Pharmacists | 1 | 2018 | 1246 | 0.08 | Why? |
| Alzheimer Disease | 1 | 2017 | 1020 | 0.08 | Why? |
| Workload | 1 | 2017 | 1887 | 0.08 | Why? |
| Pandemics | 9 | 2021 | 389249 | 0.08 | Why? |
| Mass Screening | 4 | 2018 | 8005 | 0.08 | Why? |
| Ambulatory Care Facilities | 1 | 2018 | 2063 | 0.08 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.08 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 1510 | 0.07 | Why? |
| Quality Improvement | 1 | 2018 | 2435 | 0.07 | Why? |
| Fear | 1 | 2020 | 3607 | 0.07 | Why? |
| Single-Blind Method | 2 | 2021 | 1283 | 0.07 | Why? |
| Academic Medical Centers | 1 | 2018 | 3088 | 0.07 | Why? |
| Multiple Organ Failure | 1 | 2016 | 1724 | 0.07 | Why? |
| Europe | 2 | 2021 | 12702 | 0.07 | Why? |
| Time Factors | 5 | 2019 | 31397 | 0.07 | Why? |
| Patient Satisfaction | 1 | 2018 | 2517 | 0.07 | Why? |
| Outpatients | 1 | 2018 | 3417 | 0.07 | Why? |
| Surveys and Questionnaires | 5 | 2018 | 43792 | 0.07 | Why? |
| Hospital Mortality | 4 | 2020 | 22087 | 0.07 | Why? |
| Guideline Adherence | 1 | 2017 | 2309 | 0.07 | Why? |
| Risk Assessment | 2 | 2018 | 25439 | 0.07 | Why? |
| Symptom Assessment | 1 | 2018 | 4967 | 0.07 | Why? |
| Disability Evaluation | 2 | 2018 | 671 | 0.07 | Why? |
| Follow-Up Studies | 2 | 2019 | 17020 | 0.06 | Why? |
| Atrial Fibrillation | 1 | 2018 | 2320 | 0.06 | Why? |
| Interleukin-6 | 1 | 2021 | 7522 | 0.06 | Why? |
| Syndrome | 2 | 2018 | 1310 | 0.06 | Why? |
| Chronic Disease | 1 | 2018 | 5139 | 0.06 | Why? |
| Caregivers | 1 | 2018 | 3112 | 0.06 | Why? |
| Consciousness | 2 | 2016 | 140 | 0.06 | Why? |
| Intubation, Intratracheal | 1 | 2018 | 3962 | 0.06 | Why? |
| Communication | 1 | 2020 | 5206 | 0.06 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.06 | Why? |
| Proto-Oncogene Proteins c-fos | 1 | 2021 | 50 | 0.06 | Why? |
| Inpatients | 1 | 2018 | 5161 | 0.06 | Why? |
| HSP90 Heat-Shock Proteins | 1 | 2021 | 98 | 0.05 | Why? |
| Severity of Illness Index | 5 | 2020 | 48226 | 0.05 | Why? |
| Nonverbal Communication | 1 | 2020 | 38 | 0.05 | Why? |
| Tumor Suppressor Proteins | 1 | 2021 | 165 | 0.05 | Why? |
| Respiratory Insufficiency | 2 | 2018 | 7301 | 0.05 | Why? |
| Frontal Lobe | 1 | 2021 | 191 | 0.05 | Why? |
| Cues | 1 | 2020 | 86 | 0.05 | Why? |
| Repressor Proteins | 1 | 2021 | 232 | 0.05 | Why? |
| Mental Status and Dementia Tests | 1 | 2020 | 208 | 0.05 | Why? |
| South America | 1 | 2021 | 565 | 0.05 | Why? |
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2020 | 184 | 0.05 | Why? |
| Prevalence | 4 | 2021 | 25773 | 0.05 | Why? |
| Hippocampus | 1 | 2021 | 237 | 0.05 | Why? |
| E-Selectin | 1 | 2018 | 55 | 0.05 | Why? |
| Autopsy | 1 | 2010 | 3495 | 0.05 | Why? |
| Disease Management | 1 | 2017 | 6841 | 0.05 | Why? |
| Morphine | 1 | 2018 | 71 | 0.05 | Why? |
| Walking Speed | 1 | 2018 | 77 | 0.04 | Why? |
| Anti-Inflammatory Agents | 1 | 2017 | 6153 | 0.04 | Why? |
| Lewy Bodies | 1 | 2017 | 3 | 0.04 | Why? |
| Maximum Tolerated Dose | 1 | 2017 | 65 | 0.04 | Why? |
| Neurofibrillary Tangles | 1 | 2017 | 18 | 0.04 | Why? |
| Mental Status Schedule | 1 | 2017 | 34 | 0.04 | Why? |
| Psychiatric Status Rating Scales | 1 | 2004 | 1340 | 0.04 | Why? |
| Plaque, Amyloid | 1 | 2017 | 33 | 0.04 | Why? |
| Mental Disorders | 1 | 2020 | 6742 | 0.04 | Why? |
| Depression | 2 | 2018 | 14116 | 0.04 | Why? |
| Exercise | 1 | 2017 | 6771 | 0.04 | Why? |
| Laryngoscopes | 1 | 2018 | 121 | 0.04 | Why? |
| North America | 1 | 2021 | 1400 | 0.04 | Why? |
| Retrospective Studies | 7 | 2021 | 105322 | 0.04 | Why? |
| Sensitivity and Specificity | 1 | 2017 | 22971 | 0.04 | Why? |
| Baltimore | 1 | 2017 | 220 | 0.04 | Why? |
| Translations | 1 | 2017 | 153 | 0.04 | Why? |
| Prognosis | 2 | 2017 | 32490 | 0.04 | Why? |
| Guidelines as Topic | 2 | 2020 | 2844 | 0.04 | Why? |
| Infant, Newborn | 1 | 2017 | 23105 | 0.04 | Why? |
| Anti-Bacterial Agents | 1 | 2017 | 10083 | 0.04 | Why? |
| Hospitals, University | 1 | 2007 | 4173 | 0.03 | Why? |
| Asia | 1 | 2021 | 2399 | 0.03 | Why? |
| Infusions, Intravenous | 1 | 2018 | 1224 | 0.03 | Why? |
| Triage | 1 | 2013 | 7151 | 0.03 | Why? |
| Cross-Over Studies | 1 | 2017 | 867 | 0.03 | Why? |
| Drug Therapy, Combination | 2 | 2018 | 7268 | 0.03 | Why? |
| Comorbidity | 1 | 2018 | 34796 | 0.03 | Why? |
| Cerebrovascular Circulation | 1 | 2017 | 340 | 0.03 | Why? |
| Adrenergic beta-Antagonists | 1 | 2017 | 465 | 0.03 | Why? |
| Vasoconstrictor Agents | 1 | 2017 | 714 | 0.03 | Why? |
| Hospice Care | 1 | 2018 | 347 | 0.03 | Why? |
| Adipose Tissue | 1 | 2018 | 612 | 0.03 | Why? |
| Cohort Studies | 4 | 2018 | 36005 | 0.03 | Why? |
| Radiography | 1 | 2021 | 1576 | 0.03 | Why? |
| Interpersonal Relations | 1 | 2020 | 926 | 0.03 | Why? |
| Longitudinal Studies | 2 | 2018 | 9893 | 0.03 | Why? |
| Sarcopenia | 1 | 2018 | 422 | 0.03 | Why? |
| Patient Outcome Assessment | 1 | 2017 | 707 | 0.03 | Why? |
| Treatment Failure | 1 | 2018 | 2106 | 0.03 | Why? |
| Neoplasms | 1 | 2021 | 17251 | 0.03 | Why? |
| Models, Organizational | 1 | 2018 | 908 | 0.03 | Why? |
| Respiration | 1 | 2017 | 729 | 0.03 | Why? |
| Death, Sudden, Cardiac | 1 | 2017 | 522 | 0.03 | Why? |
| Evidence-Based Practice | 1 | 2018 | 693 | 0.03 | Why? |
| Indiana | 1 | 2012 | 236 | 0.03 | Why? |
| Morals | 1 | 2017 | 483 | 0.03 | Why? |
| Self Efficacy | 1 | 2017 | 717 | 0.03 | Why? |
| Fatal Outcome | 1 | 2021 | 3438 | 0.03 | Why? |
| Medicine | 1 | 2017 | 485 | 0.03 | Why? |
| Exercise Test | 1 | 2017 | 911 | 0.03 | Why? |
| Patient Transfer | 1 | 2018 | 898 | 0.03 | Why? |
| Tomography, X-Ray Computed | 1 | 2017 | 25144 | 0.03 | Why? |
| Defibrillators, Implantable | 1 | 2017 | 624 | 0.03 | Why? |
| Socioeconomic Factors | 2 | 2018 | 8495 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2017 | 2324 | 0.03 | Why? |
| Health Personnel | 1 | 2020 | 29646 | 0.03 | Why? |
| Dexamethasone | 1 | 2021 | 2055 | 0.03 | Why? |
| Pharmacy Service, Hospital | 1 | 2018 | 645 | 0.02 | Why? |
| Interdisciplinary Communication | 1 | 2017 | 1425 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2018 | 4260 | 0.02 | Why? |
| Feasibility Studies | 1 | 2018 | 3467 | 0.02 | Why? |
| Analgesics, Opioid | 1 | 2018 | 1070 | 0.02 | Why? |
| Professional Role | 1 | 2018 | 1280 | 0.02 | Why? |
| Continuity of Patient Care | 1 | 2018 | 1574 | 0.02 | Why? |
| Research Design | 1 | 2004 | 5830 | 0.02 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 1261 | 0.02 | Why? |
| Intention | 1 | 2017 | 1380 | 0.02 | Why? |
| Equipment Design | 1 | 2018 | 3095 | 0.02 | Why? |
| Incidence | 2 | 2018 | 25622 | 0.02 | Why? |
| Perception | 1 | 2017 | 2827 | 0.02 | Why? |
| ROC Curve | 1 | 2018 | 6024 | 0.02 | Why? |
| Resilience, Psychological | 1 | 2020 | 2329 | 0.02 | Why? |
| Life Style | 1 | 2018 | 2708 | 0.02 | Why? |
| Infant | 2 | 2019 | 30274 | 0.02 | Why? |
| Body Mass Index | 1 | 2018 | 4306 | 0.02 | Why? |
| Acute Disease | 1 | 2018 | 6029 | 0.02 | Why? |
| Survival Rate | 1 | 2019 | 9206 | 0.02 | Why? |
| Occupational Health | 1 | 2020 | 3965 | 0.02 | Why? |
| Adrenal Cortex Hormones | 1 | 2021 | 6537 | 0.02 | Why? |
| Child, Preschool | 2 | 2019 | 36283 | 0.02 | Why? |
| Evidence-Based Medicine | 1 | 2017 | 3228 | 0.02 | Why? |
| Adenosine Monophosphate | 1 | 2021 | 5652 | 0.02 | Why? |
| Alanine | 1 | 2021 | 5687 | 0.02 | Why? |
| Anxiety | 2 | 2020 | 17311 | 0.02 | Why? |
| Family | 1 | 2017 | 2909 | 0.02 | Why? |
| Disease Models, Animal | 1 | 2021 | 10998 | 0.02 | Why? |
| Referral and Consultation | 1 | 2019 | 4816 | 0.02 | Why? |
| Consensus | 1 | 2017 | 6345 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2018 | 9537 | 0.02 | Why? |
| Adaptation, Psychological | 1 | 2020 | 4996 | 0.01 | Why? |
| Mice | 1 | 2021 | 21357 | 0.01 | Why? |
| Sex Factors | 1 | 2018 | 11014 | 0.01 | Why? |
| Patient Admission | 1 | 2018 | 5250 | 0.01 | Why? |
| France | 1 | 2017 | 12074 | 0.01 | Why? |
| United Kingdom | 1 | 2020 | 18046 | 0.01 | Why? |
| Cross-Sectional Studies | 2 | 2017 | 53120 | 0.01 | Why? |
| Case-Control Studies | 1 | 2018 | 17671 | 0.01 | Why? |
| Inflammation | 1 | 2021 | 13255 | 0.01 | Why? |
| Disease Progression | 1 | 2017 | 13580 | 0.01 | Why? |
| Age Factors | 1 | 2018 | 21039 | 0.01 | Why? |
| Global Health | 1 | 2020 | 13911 | 0.01 | Why? |
| Italy | 1 | 2019 | 38444 | 0.01 | Why? |
| Biomarkers | 1 | 2018 | 23361 | 0.01 | Why? |
| Mental Health | 1 | 2020 | 15770 | 0.01 | Why? |
| Animals | 1 | 2021 | 78931 | 0.01 | Why? |
| Antiviral Agents | 1 | 2021 | 41703 | 0.01 | Why? |
| Adolescent | 1 | 2017 | 86841 | 0.00 | Why? |
| Young Adult | 1 | 2017 | 93724 | 0.00 | Why? |